EGFR and lung cancer: Non–small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases (2), and mutant EGFR is one of its most common oncogenic drivers (10%–40%), which is associated with poor prognosis and limited therapeutic efficacy (3–5).